華海藥業HB0025注射液Ⅲ期臨床啓動，3億研發加碼多靶點抗癌藥領域！

摩熵醫藥大數據

2025/12/29

12月26日，據$華海藥業(600521)發布公告，其下屬子公司上海華奧泰生物的 HB0025 聯合化療一線治療鱗狀和非鱗狀非小細胞肺癌經過與國家藥品監督管理局藥品審評中心Ⅱ期臨床試驗結束/Ⅲ期臨床試驗啓動前的會議溝通，公司將正式啓動 HB0025注射液的III期臨床試驗。截圖來源：企業公告HB0025 是由華奧泰自主研發的一款創新型抗PD-L1/VEGF雙特異性融合蛋白，同時靶向腫瘤免疫逃逸...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2595973288"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2595973288\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2595973288?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-12-29 15:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2595973288","market":"hk","top_or_hot":-1,"title":"華海藥業HB0025注射液Ⅲ期臨床啓動，3億研發加碼多靶點抗癌藥領域！","media":"摩熵醫藥大數據","content":"<div>\n<p>12月26日，據$華海藥業(600521)發布公告，其下屬子公司上海華奧泰生物的 HB0025 聯合化療一線治療鱗狀和非鱗狀非小細胞肺癌經過與國家藥品監督管理局藥品審評中心Ⅱ期臨床試驗結束/Ⅲ期臨床試驗啓動前的會議溝通，公司將正式啓動 HB0025注射液 的III期臨床試驗。截圖來源：企業公告HB0025 是由華奧泰自主研發的一款創新型抗PD-L1/VEGF雙特異性融合蛋白，同時靶向腫瘤免疫逃逸...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229152223a6dc0065&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>華海藥業HB0025注射液Ⅲ期臨床啓動，3億研發加碼多靶點抗癌藥領域！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n華海藥業HB0025注射液Ⅲ期臨床啓動，3億研發加碼多靶點抗癌藥領域！\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">摩熵醫藥大數據</strong><span class=\"h-time small\">2025-12-29 15:01</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>12月26日，據$華海藥業(600521)發布公告，其下屬子公司上海華奧泰生物的 HB0025 聯合化療一線治療鱗狀和非鱗狀非小細胞肺癌經過與國家藥品監督管理局藥品審評中心Ⅱ期臨床試驗結束/Ⅲ期臨床試驗啓動前的會議溝通，公司將正式啓動 HB0025注射液 的III期臨床試驗。截圖來源：企業公告HB0025 是由華奧泰自主研發的一款創新型抗PD-L1/VEGF雙特異性融合蛋白，同時靶向腫瘤免疫逃逸...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229152223a6dc0065&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229152223a6dc0065&s=b\">摩熵醫藥大數據</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0417516902.SGD","symbol_name":"Allianz China Equity Cl AT Acc SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229152223a6dc0065&s=b","article_id":"2595973288","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229152223a6dc0065&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2595973288","pubTimestamp":1766991697,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"12月26日，據$華海藥業發布公告，其下屬子公司上海華奧泰生物的 HB0025 聯合化療一線治療鱗狀和非鱗狀非小細胞肺癌經過與國家藥品監督管理局藥品審評中心Ⅱ期臨床試驗結束/Ⅲ期臨床試驗啓動前的會議溝通，公司將正式啓動 HB0025注射液 的III期臨床試驗。根據和CDE的會議溝通，華海藥業將啓動兩項確證性III期臨床試驗。截至目前，華海藥業已在 HB0025 項目上已合計投入研發費用約人民幣32,597萬元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","BK1161":"生物科技","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","BK1574":"生物医药B类股","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","09926":"康方生物","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC"},"translate_title":"Huahai Pharmaceutical's HB0025 injection phase III clinical trial started, with 300 million research and development increasing the field of multi-target anticancer drugs!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":0.9},"content_text":"12月26日，據$華海藥業(600521)發布公告，其下屬子公司上海華奧泰生物的 HB0025 聯合化療一線治療鱗狀和非鱗狀非小細胞肺癌經過與國家藥品監督管理局藥品審評中心Ⅱ期臨床試驗結束/Ⅲ期臨床試驗啓動前的會議溝通，公司將正式啓動 HB0025注射液 的III期臨床試驗。截圖來源：企業公告HB0025 是由華奧泰自主研發的一款創新型抗PD-L1/VEGF雙特異性融合蛋白，同時靶向腫瘤免疫逃逸通路PD-L1和腫瘤血管生成通路VEGF。該藥物設計實現了兩個靶點的高親和力結合，協同調控腫瘤免疫微環境與血管生成，具備「免疫增強+抗血管」雙重抗腫瘤機制。根據和CDE的會議溝通，華海藥業將啓動兩項確證性III期臨床試驗。截圖來源：摩熵醫藥數據庫-全球藥物研發數據庫目前，$康方生物(HK9926)研發的 依沃西單抗（PD-1/VEGF雙抗）已在中國獲批上市，BMS的 PM8002（PD-L1/VEGF雙抗）、$PFE(PFE)的 SSGJ-707（PD-1/VEGF雙抗）已進入臨床III期。華奧泰在2025年ESMO會議（歐洲腫瘤內科學會）公布的 HB0025 聯合化療一線治療晚期肺鱗癌和肺腺癌II期臨床數據，具有較好的客觀緩解率和疾病控制率，尤其在PD-L1陰性人群中ORR的響應率高，3級以上免疫相關不良事件（irAEs）發生率低。HB0025國內研發狀態（部分）截圖來源：摩熵醫藥-全球藥物研發數據庫此外，HB0025 多個II期臨床試驗正在評估中，涵蓋包括子宮內膜癌、結直腸癌、三陰乳腺癌等多種實體瘤。截至目前，華海藥業已在 HB0025 項目上已合計投入研發費用約人民幣32,597萬元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}